Dr. Jusheng An 安菊生
Chief Physician
Department of Gynecologic Oncology, Cancer Hospital, Chinese Academy of Medical Sciences (National Cancer Center), Beijing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Comprehensive treatment of gynecologic tumors with a focus on radiotherapy. Expertise in conventional and 3D radiotherapy for cervical and endometrial cancer.
Dr. An earned a medical degree from Southeast University in 2002 and a PhD from Peking Union Medical College in 2008. Since then, Dr. An has worked in the Department of Gynecologic Oncology at Cancer Hospital, Chinese Academy of Medical Sciences. In 2013, Dr. An completed advanced training in radiotherapy at the Medical University of Vienna. Research interests include 3D brachytherapy for cervical cancer.
Name order: in Chinese the family name comes first (An Jusheng). Papers usually list the name as Jusheng An or An J.
Selected publications
38 papers on PubMed matched by name and affiliation; 7 as first or senior author since 2016. Most recent first- or senior-author papers:
- Gynecol Oncol, 2025 (first author): Sacituzumab govitecan in Chinese patients with recurrent/metastatic cervical cancer: Results from the phase 2 EVER-132-003 basket study (NCT05119907). PubMed 40972504
- Radiat Oncol, 2025 (senior author): Risk stratification of node-positive early-stage cervical cancer treated with radical hysterectomy followed by chemoradiotherapy: a retrospective single-center study. PubMed 40361146
- BMC Cancer, 2025 (senior author): Low pretreatment prognostic nutritional index predicts unfavorable survival in stage III-IVA squamous cervical cancer undergoing chemoradiotherapy. PubMed 40022054
- Medicine (Baltimore), 2024 (senior author): Cervical metastasis of breast cancer: A case report and literature review. PubMed 39121246
- Front Immunol, 2023 (first author): Efficacy and safety of serplulimab plus nab-paclitaxel in previously treated patients with PD-L1-positive advanced cervical cancer: a phase II, single-arm study. PubMed 37153587
- Clin Cancer Res, 2022 (first author): Efficacy and Safety of the Anti-PD-L1 mAb Socazolimab for Recurrent or Metastatic Cervical Cancer: a Phase I Dose-Escalation and Expansion Study. PubMed 36136294
- Oncotarget, 2017 (senior author): Primary malignant melanoma of the cervix: Report of 14 cases and review of literature. PubMed 29069859
- Zhonghua Fu Chan Ke Za Zhi, 2013 (first author): [Study of the radiotherapy modality for patients with stage IIb-IIIb cervical stump cancer]. PubMed 24332130
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion